氯沙坦及依那普利对糖尿病肾病的治疗观察

Observation on the treatment of losartan and enalapril in diabetes nephropathy

目的 观察血管紧张素Ⅱ受体阻断剂（ARB）与血管紧张素转化酶抑制剂（ACEI）对糖尿病。肾病（DN）疗效及其意义。方法 52例2型糖尿病肾病患者，随机分为两组，其中氯沙坦组26例，氯沙坦50～100mg／d；依那普利组26例，依那普利10mg／d，采用比色法检测尿蛋白，全自动血生化分析仪测定血尿素氮和肌酐。结果 氯沙坦组和依那普利组治疗后平均动脉压均较治疗前有显著下降（P〈0．05），两组之间平均动脉压相比较无显著差异（P〉0．05）。氯沙坦和依那普利均具有减少糖尿病。肾病患者尿蛋白的作用，二者之间无明显差异。结论 氯沙坦和依那普利在减少糖尿病肾病患者尿蛋白的作用方面疗效相当。

Objective To observe the treatment and significance of angiotensin Ⅱ receptor blockers and angiotensin conver ting enzyme inhibitors on the diabetes nephropathy. Methods .52 in-patients and out-patients with Ⅱ diabetes mellitus were randomly divided into losartan group and enalapril group. The patients in losartan group were treated with 50 100mg·d losartan. Another 26 patients were treated with 10 mg·d enalapril. The urine protein was measured by colorimetry and the blood urea nitrogen and creatinine by biochemical analyzer. Results After the treatment, the mean arterial pressure declined obviously in both groups （ P 〈 0.05 ）, but there was no significant difference between them. Both losartan and enalapril can decrease the level of urine protein in patients with diabetes mellitus, and there was no significant difference between them. Conclusion Kosartan and enalapril can effectively decrease the level of urine protein in patients with diabetes mdlitus.